Avelumab for the treatment of patients with Merkel cell carcinoma
Merkel cell carcinoma is a rare and aggressive skin tumor that is difficult to treat even at early stages. Treatment approaches for advanced disease are limited and standard chemotherapy provides short-lived disease control in half of patients without significant impact on the overall survival. The...
Main Authors: | K. V. Orlova, N. N. Petenko, V. V. Nazarova, L. V. Demidov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2020-07-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/5708 |
Similar Items
-
Immunotherapy in Merkel cell carcinoma: role of Avelumab
by: Palla AR, et al.
Published: (2018-03-01) -
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial
by: Howard L. Kaufman, et al.
Published: (2018-01-01) -
Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program
by: Giovanni Grignani, et al.
Published: (2021-02-01) -
Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma
by: Dirk Schadendorf, et al.
Published: (2017-10-01) -
Favorable Response to Treatment with Avelumab in an HIV-Positive Patient with Advanced Merkel Cell Carcinoma Previously Refractory to Chemotherapy
by: Mohammed U. Al Homsi, et al.
Published: (2018-07-01)